U.S. STEM CELL, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-12-04: Form 8-K; Period of report 2015-12-03; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events; Details 1.01.
- 2015-11-04: Form 8-K; Period of report 2015-11-04; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 3.01.
- 2015-10-02: Form 8-K; Period of report 2015-10-01; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events; Details 1.01.
- 2015-06-22: Form 8-K; Period of report 2015-06-17; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-12-04 | 8-K | 2015-12-03 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 On December 3, 2015, (the “Closing Date”), U.S. Stem Cell, Inc., a Florida corporation (the “Company”), entered into a securities purchase agreement dated as of the Closing Date (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (“Magna”). 2.03 The disclosure set forth under Item 1.01 of this Report is incorporated by reference into this Item. 8.01 On December 4, 2015, the Company issued a press release announcing the issuance of the Convertible Note to Magna, a copy of which is attached to this Report as Exhibit 99.1. | usstemcell8k120315.htm |
| 2015-11-04 | 8-K | 2015-11-04 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.01 In connection with the Company’s reverse stock split, the Financial Industry Regulatory Authority has assigned the Company a new stock symbol, BHRTD. 5.03 The Company amended its Articles of Incorporation to change its name to U.S. Stem Cell, Inc. and to implement a reverse stock split in the ratio of 1 share for every 1,000 shares of common stock. | usstemcell8k110315.htm |
| 2015-10-02 | 8-K | 2015-10-01 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 8.01 Other Events | 1.01 On October 1, 2015 (the “Closing Date”), Bioheart, Inc., a Florida corporation (the “Company”), entered into a securities purchase agreement dated as of the Closing Date (the “Purchase Agreement”) with Magna Equities II, LLC, a New York limited liability company (“Magna”). 2.03 The disclosure set forth under Item 1.01 of this Report is incorporated by reference into this Item. 8.01 On October 2nd, 2015, the Company issued a press release announcing the issuance of the Convertible Note to Magna, a copy of which is attached to this Report as Exhibit 99.1. | bioheart8k100115.htm |
| 2015-06-22 | 8-K | 2015-06-17 | 8.01 Other Events | 8.01 On November 10, 2014, the Company was served with a lawsuit by an alleged assignee and a guarantor to a Loan Guarantee, Payment and Security Agreement. | bioheart_8k.htm |
| 2015-02-06 | 8-K | 2015-02-04 | 7.01 Regulation FD Disclosure | 7.01 On February 4, 2015, the Company presented a power point presentation (the “Presentation”). | bioheart_8k.htm |
| 2015-02-06 | 8-K | 2015-02-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.07 At the Annual of Stockholders (the “Annual Meeting”) of the Company held on February 2, 2015, the stockholders of the Company approved each of the proposals set forth below by the final voting results (based on 610,475,357 common shares and 20,000,000 Series A Preferred Shares with voting rights) set forth below. | bioheart_8k.htm |
| 2015-01-16 | 8-K | 2015-01-16 | 7.01 Regulation FD Disclosure | 7.01 REGULATION FD DISCLOSURE. | d32019.htm |